NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics (CRSP) recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile...